Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Trial Profile

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Fosbretabulin (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 15 Nov 2016 Status changed from recruiting to completed.
    • 06 Jan 2016 According to an OXiGENE media release, the US FDA granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors, in January 2016.
    • 05 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top